Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (CLL2-GiVe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02758665
Recruitment Status : Active, not recruiting
First Posted : May 2, 2016
Last Update Posted : February 28, 2019
German CLL Study Group
Roche Pharma AG
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
Stephan Stilgenbauer, University of Ulm

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : March 2022